Clinical trials recruiting for Multiple sclerosis
445
Recruiting trials
44
US states with sites
57
Countries
20%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Ublituximab | 8 |
| Ocrelizumab | 7 |
| Fingolimod | 3 |
| Ozanimod | 3 |
| Rituximab | 3 |
| UCAR T-cell | 3 |
| Cyclophosphamide | 2 |
| Dimethyl Fumarate | 2 |
| Fludarabine | 2 |
| Intravenous steroid | 2 |
| Metformin | 2 |
| Methylprednisolone | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 40 |
| Massachusetts | 36 |
| Texas | 31 |
| Illinois | 30 |
| Maryland | 29 |
| New York | 26 |
| Ohio | 26 |
| Florida | 24 |
| Michigan | 21 |
| Colorado | 17 |
| Missouri | 17 |
| Washington | 17 |
Top cities
Boston, Massachusetts 28Chicago, Illinois 24New York, New York 23St Louis, Missouri 17Bethesda, Maryland 15Cleveland, Ohio 15Houston, Texas 14Seattle, Washington 13Baltimore, Maryland 12Birmingham, Alabama 12
Self-screener
Recruiting trials
- "Balance, Gait, and Motion Analysis in Multiple Sclerosis"
- "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- 3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)
- A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
- A Palliative Care Model Impact on Knowledge and Attitudes
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
- A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
- A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
- A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
- A Specialized Diet for Multiple Sclerosis
- A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
- A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- A Study of AZD0120 in Autoimmune Diseases
- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
- A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
- A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
- A Study of the MIND Diet for Persons With Multiple Sclerosis
- A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
- A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
- AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
- AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
- AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
- ATLG Levels in Autologous HSCT for Multiple Sclerosis
- Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.
- Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI
- Adverse Childhood Experiences in Patients With MS: Impact on Quality of Life and on Coping Strategies Towards the Disease and Its Treatment
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
- An Individualized-health eLibrary App for People With Multiple Sclerosis
- An Online Nurse-Led Purpose-Focused Group Program for Adult Women With Multiple Sclerosis: Effects on Meaning and Quality of Life
- An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
- Analysis of Balance Disorders After Botulinum Toxin Treatment in the Rectus Femoris in Patients With a Stiff Knee Gait
- Application of ihMT MRI in Multiple Sclerosis
- Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
- Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
- Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis
- Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
- Assessment of Synaptic Density in MS
- Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
- At Home Use of Stimulation Suits for Managing MS Symptoms
- Auditory Functions in Patients With Multiple Sclerosis
- Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- Biomarkers in Autoimmune Disease of Nervous System
- Biomarkers of Synaptic Damage in Multiple Sclerosis
- Blood Flow Restriction And Veterans With MS
- Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)
- Body Awareness, Trunk Stability, and Arm Function in MS
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
- BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
- Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
- Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
- CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
- Cannabis (THC vs. CBD) in Multiple Sclerosis
- Cannabis as a Complementary Treatment in Multiple Sclerosis
- Care in Multiple Sclerosis (MS)
- Caregiver Burden in Caregivers of Patients With Multiple Sclerosis
- Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
- Central Vein Sign in Multiple Sclerosis Extension Study
- China National Registry of Neuro-Inflammatory Diseases
- Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
- Classification of Upper and Lower Limb Spasticity Patterns and Their Impact on Quality of Life in Patients With Multiple Sclerosis
- Clinical Applications of Advanced Ophthalmic Imaging
- Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
- Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.
- Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
- Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Clinical and Instrumental Treatment's Predictors in Subjects With Neurological Diseases Using G-EO Robotic System
- Clinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis
- Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Related conditions
Trials recruiting for Multiple sclerosis often also study these conditions. Each links to its own recruiting-trial list.
Parkinson's disease 522Multiple Sclerosis (Relapsing Remitting) 17Stroke 94Lupus 332Multiple Sclerosis (MS) 14Alzheimer's disease 617Multiple Sclerosis (MS) - Relapsing-remitting 12Relapsing Multiple Sclerosis 11Tuberous Sclerosis 10Rheumatoid arthritis 314
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Multiple sclerosis trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.